Amendments to Various National Indian Gaming Commission Regulations, 42775 [E9-20511]
Download as PDF
Federal Register / Vol. 74, No. 163 / Tuesday, August 25, 2009 / Rules and Regulations
the human environment. Therefore,
neither an environmental assessment
nor an environmental impact statement
is required.
srobinson on DSKHWCL6B1PROD with RULES
VI. What is the Economic Impact of
This Rule?
FDA has examined the impacts of the
direct final rule under Executive Order
12866 and the Regulatory Flexibility Act
(5 U.S.C. 601–612), and the Unfunded
Mandates Reform Act of 1995 (Public
Law 104–4). Executive Order 12866
directs agencies to assess all costs and
benefits of available regulatory
alternatives and, when regulation is
necessary, to select regulatory
approaches that maximize net benefits
(including potential economic,
environmental, public health and safety,
and other advantages; distributive
impacts; and equity). The agency
believes that this direct final rule is not
a significant regulatory action under the
Executive order.
The Regulatory Flexibility Act
requires agencies to analyze regulatory
options that would minimize any
significant impact of a rule on small
entities. Because we do not believe any
companies are currently selling or
producing these devices, the agency
certifies that the final rule will not have
a significant economic impact on a
substantial number of small entities.
Section 202(a) of the Unfunded
Mandates Reform Act of 1995 requires
that agencies prepare a written
statement, which includes an
assessment of anticipated costs and
benefits, before proposing ‘‘any rule that
includes any Federal mandate that may
result in the expenditure by State, local,
and tribal governments, in the aggregate,
or by the private sector, of $100,000,000
or more (adjusted annually for inflation)
in any one year.’’ The current threshold
after adjustment for inflation is $133
million, using the most current (2008)
Implicit Price Deflator for the Gross
Domestic Product. FDA does not expect
this final rule to result in any 1–year
expenditure that would meet or exceed
this amount.
VII. How Does the Paperwork
Reduction Act of 1995 Apply to This
Rule?
This direct final rule contains no
collection of information. Therefore,
clearance by the Office of Management
and Budget under the Paperwork
Reduction Act of 1995 (44 U.S.C. 3501–
3520) is not required.
VIII. What are the Federalism Impacts
of This Rule?
FDA has analyzed this direct final
rule in accordance with the principles
VerDate Nov<24>2008
19:42 Aug 24, 2009
Jkt 217001
set forth in Executive Order 13132. FDA
has determined that the rule does not
contain policies that have substantial
direct effects on the States, on the
relationship between the National
Government and the States, or on the
distribution of power and
responsibilities among the various
levels of government. Accordingly, the
agency has concluded that the rule does
not contain policies that have
federalism implications as defined in
the Executive order and, consequently,
a federalism summary impact statement
is not required.
IX. How Do You Submit Comments on
This Rule?
Interested persons may submit to the
Division of Dockets Management (see
ADDRESSES) written or electronic
comments regarding this document.
Submit a single copy of electronic
comments or two paper copies of any
mailed comments, except that
individuals may submit one paper copy.
Comments are to be identified with the
docket number found in brackets in the
heading of this document. Received
comments may be seen in the Division
of Dockets Management between 9 a.m.
and 4 p.m., Monday through Friday.
List of Subjects in 21 CFR Part 866
Biologics, Laboratories, and Medical
devices.
Therefore, under the Federal Food,
Drug, and Cosmetic Act and under
authority delegated to the Commissioner
of Food and Drugs, it is proposed to
amend 21 CFR part 866 as follows:
■
PART 866—IMMUNOLOGY AND
MICROBIOLOGY DEVICES
1. The authority citation for 21 CFR
part 866 continues to read as follows:
■
Authority: 21 U.S.C. 351, 360, 360c, 360e,
360j, 371.
2. Section 866.3305 is amended by
removing paragraph (c) and by revising
paragraph (b) to read as follows:
■
§ 866.3305 Herpes simplex virus
serological assays.
*
*
*
*
*
(b) Classification. Class II (special
controls). The device is classified as
class II (special controls). The special
control for the device is FDA’s guidance
document entitled ‘‘Class II Special
Controls Guidance Document: Herpes
Simplex Virus Types 1 and 2
Serological Assays.’’ For availability of
the guidance document, see § 866.1(e).
PO 00000
Frm 00005
Fmt 4700
Sfmt 4700
42775
Dated: August 17, 2009.
David Horowitz,
Assistant Commissioner for Policy.
[FR Doc. E9–20411 Filed 8–24–09; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF THE INTERIOR
National Indian Gaming Commission
25 CFR Parts 502, 514, 531, 533, 535,
537, 539, 556, 558, 571, and 573
RIN 3141–0001
Amendments to Various National
Indian Gaming Commission
Regulations
AGENCY: National Indian Gaming
Commission.
ACTION: Final rule; delay of effective
date.
SUMMARY: The National Indian Gaming
Commission (‘‘NIGC’’) announces the
extension of the effective date on the
final rule concerning various
amendments to the National Indian
Gaming Commission regulations. The
final rule was published in the Federal
Register on July 27, 2009. The
Commission has changed the effective
date to December 31, 2009, in order to
extend the transition time.
DATES: Effective Date: The effective date
for the final rule published July 27,
2009, at 74 FR 36926, is delayed from
August 26, 2009, until December 31,
2009.
FOR FURTHER INFORMATION CONTACT:
Rebecca Chapman, Staff Attorney,
Office of General Counsel, at (202) 632–
7003; fax (202) 632–7066 (not toll-free
numbers).
Congress
established the National Indian Gaming
Commission under the Indian Gaming
Regulatory Act of 1988 (25 U.S.C. 2701–
21) (‘‘IGRA’’) to regulate gaming on
Indian lands. The NIGC issued a final
rule updating various NIGC regulations
and streamlining procedures, which was
published in the Federal Register on
July 27, 2009 (74 FR 36926). The final
rule provided an effective date of
August 26, 2009. The NIGC is extending
the effective date to December 31, 2009.
SUPPLEMENTARY INFORMATION:
Philip N. Hogen,
Chairman.
Norman H. DesRosiers,
Vice Chairman.
[FR Doc. E9–20511 Filed 8–24–09; 8:45 am]
BILLING CODE 7565–01–P
E:\FR\FM\25AUR1.SGM
25AUR1
Agencies
[Federal Register Volume 74, Number 163 (Tuesday, August 25, 2009)]
[Rules and Regulations]
[Page 42775]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-20511]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF THE INTERIOR
National Indian Gaming Commission
25 CFR Parts 502, 514, 531, 533, 535, 537, 539, 556, 558, 571, and
573
RIN 3141-0001
Amendments to Various National Indian Gaming Commission
Regulations
AGENCY: National Indian Gaming Commission.
ACTION: Final rule; delay of effective date.
-----------------------------------------------------------------------
SUMMARY: The National Indian Gaming Commission (``NIGC'') announces the
extension of the effective date on the final rule concerning various
amendments to the National Indian Gaming Commission regulations. The
final rule was published in the Federal Register on July 27, 2009. The
Commission has changed the effective date to December 31, 2009, in
order to extend the transition time.
DATES: Effective Date: The effective date for the final rule published
July 27, 2009, at 74 FR 36926, is delayed from August 26, 2009, until
December 31, 2009.
FOR FURTHER INFORMATION CONTACT: Rebecca Chapman, Staff Attorney,
Office of General Counsel, at (202) 632-7003; fax (202) 632-7066 (not
toll-free numbers).
SUPPLEMENTARY INFORMATION: Congress established the National Indian
Gaming Commission under the Indian Gaming Regulatory Act of 1988 (25
U.S.C. 2701-21) (``IGRA'') to regulate gaming on Indian lands. The NIGC
issued a final rule updating various NIGC regulations and streamlining
procedures, which was published in the Federal Register on July 27,
2009 (74 FR 36926). The final rule provided an effective date of August
26, 2009. The NIGC is extending the effective date to December 31,
2009.
Philip N. Hogen,
Chairman.
Norman H. DesRosiers,
Vice Chairman.
[FR Doc. E9-20511 Filed 8-24-09; 8:45 am]
BILLING CODE 7565-01-P